Related Experiment Video

Updated: Jul 12, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

The use of hypomethylating agents in the treatment of hematologic malignancies

Jane E Kihslinger1, Lucy A Godley

  • 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

Leukemia & Lymphoma
|September 6, 2007
PubMed

Insights

Hypomethylating agents like 5-azacitidine and decitabine show 40-50% response rates in myelodysplastic syndromes and acute myeloid leukemia. These epigenetic drugs are well-tolerated, with myelosuppression as the main side effect.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic alterations, including DNA methylation and histone modifications, are hallmarks of cancer.
  • Hypomethylating agents 5-azacitidine and decitabine are crucial in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Purpose of the Study:

  • To review the efficacy and safety of hypomethylating agents in hematologic malignancies.
  • To discuss the current understanding and future directions of epigenetic therapies in cancer treatment.

Main Methods:

  • Analysis of clinical data regarding response rates and side effects of 5-azacitidine and decitabine.
  • Review of postulated mechanisms of action, including DNA hypomethylation and gene expression induction.
  • Exploration of potential combination therapies with other epigenetic modifiers.

Main Results:

  • Repeated cycles of low-dose 5-azacitidine and decitabine yield overall response rates of 40-50% in MDS and AML.
  • These agents are generally well-tolerated, with myelosuppression being the primary dose-limiting toxicity.
  • The exact molecular mechanisms underlying their therapeutic effects are still under investigation.

Conclusions:

  • Hypomethylating agents are effective and tolerable treatments for MDS and AML.
  • Future research should focus on elucidating their precise mechanisms and exploring combination strategies, such as with histone deacetylase inhibitors, to enhance therapeutic outcomes.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution13:47

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

Related Concept Videos

Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...